Brii Biosciences Doses First Patient With mRNA Cancer Vaccine BRII-5395

Company: Brii Biosciences · Asset: BRII-5395 · Modality: mRNA Therapeutic Cancer Vaccine · Indication: HBV-Related Hepatocellular Carcinoma · Date: August 20, 2026 Summary Brii Biosciences disclosed that the first participant was dosed on August 12 with BRII-5395, an internally discovered mRNA therapeutic cancer vaccine, in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Terremoto – $108M Series C Degrader Platform
Nurix–Roche BTK Degrader Deal Closes
Silence Therapeutics Prices Upsized $175 Million Offering After Positive Divesiran Data
Lilly + Ascidian – $1.9B RNA Exon Editing Deal